NCT01742221View on ClinicalTrials.gov

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

PHASE1CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions

Hematopoietic Syndrome Due to Acute Radiation Syndrome

Interventions

BIOLOGICAL

HemaMax

single subcutaneous 12 microgram dose of HemaMax

DRUG

Placebo

single subcutaneous dose

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

Sponsors

Lead Sponsor

Neumedicines Inc.

All Listed Sponsors

collaborator

Department of Health and Human Services

FED

lead

Neumedicines Inc.

INDUSTRY

NCT01742221 - Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure | Biotech Hunter | Biotech Hunter